Tower Research Capital LLC (Trc) Essa Pharma Inc. Transaction History

Tower Research Capital LLC (Trc)

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$2.6 - $3.34 $70 - $90	27 New	27 $0
Q4 2022 Feb 10, 2023	SELL	$1.5 - $4.82 $24,970 - $80,238	-16,647 Reduced 99.33%	113 $0
Q3 2022 Nov 10, 2022	SELL	$1.75 - $3.44 $9,114 - $17,915	-5,208 Reduced 23.71%	16,760 $30,000
Q2 2022 Aug 15, 2022	BUY	$3.15 - $7.94 $67,765 - $170,813	21,513 Added 4728.13%	21,968 $69,000
Q1 2022 May 12, 2022	BUY	$6.18 - $14.44 $642 - $1,501	104 Added 29.63%	455 $3,000
Q4 2021 Feb 14, 2022	SELL	$7.8 - $14.38 $51,004 - $94,030	-6,539 Reduced 94.91%	351 $5,000
Q3 2021 Nov 15, 2021	BUY	$7.76 - $29.37 $53,466 - $202,359	6,890 New	6,890 $55,000
Q1 2020 May 15, 2020	SELL	$3.23 - $5.87 $287 - $522	-89 Closed	0 $0
Q4 2019 Feb 07, 2020	SELL	$3.05 - $6.0 $338 - $666	-111 Reduced 55.5%	89 $0
Q3 2019 Nov 05, 2019	BUY	$1.46 - $3.37 $292 - $674	200 New	200 $1,000
Q4 2018 Feb 14, 2019	SELL	$1.9 - $4.02 $760 - $1,607	-400 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$2.67 - $4.23 $534 - $846	200 Added 100.0%	400 $1,000
Q2 2018 Aug 15, 2018	BUY	$3.2 - $4.74 $640 - $948	200 New	200 $1,000

35.1M

15.8K

21K

Ticker EPIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,073,100
Market Cap $72.3M
Description
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreem...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.